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ABSTRACT The human genome displays a rich fossil record of past gammaretrovirus
infections, yet no current epidemic is evident, despite environmental exposure to vi-
ruses that infect human cells in vitro. Feline leukemia viruses (FeLVs) rank high on
this list, but neither domestic nor workplace exposure has been associated with de-
tectable serological responses. Nonspecific inactivation of gammaretroviruses by se-
rum factors appears insufficient to explain these observations. To investigate further,
we explored the susceptibilities of primary and established human cell lines to
FeLV-B, the most likely zoonotic variant. Fully permissive infection was common in
cancer-derived cell lines but was also a feature of nontransformed keratinocytes and
lung fibroblasts. Cells of hematopoietic origin were generally less permissive and
formed discrete groups on the basis of high or low intracellular protein expression
and virion release. Potent repression was observed in primary human blood mono-
nuclear cells and a subset of leukemia cell lines. However, the early steps of reverse
transcription and integration appear to be unimpaired in nonpermissive cells. FeLV-B
was subject to G¡A hypermutation with a predominant APOBEC3G signature in
partially permissive cells but was not mutated in permissive cells or in nonpermis-
sive cells that block secondary viral spread. Distinct cellular barriers that protect pri-
mary human blood cells are likely to be important in protection against zoonotic in-
fection with FeLV.
IMPORTANCE Domestic exposure to gammaretroviruses such as feline leukemia vi-
ruses (FeLVs) occurs worldwide, but the basis of human resistance to infection re-
mains incompletely understood. The potential threat is evident from the human ge-
nome sequence, which reveals many past epidemics of gammaretrovirus infection,
and from recent cross-species jumps of gammaretroviruses from rodents to primates
and marsupials. This study examined resistance to infection at the cellular level with
the most prevalent human cell-tropic FeLV variant, FeLV-B. We found that blood
cells are uniquely resistant to infection with FeLV-B due to the activity of cellular en-
zymes that mutate the viral genome. A second block, which appears to suppress vi-
ral gene expression after the viral genome has integrated into the host cell genome,
was identified. Since cells derived from other normal human cell types are fully sup-
portive of FeLV replication, innate resistance of blood cells could be critical in pro-
tecting against cross-species infection.
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Completion of the draft human genome sequence in 2001 revealed that a remark-able 8% of the genome consists of retrovirus-like elements (1). Although the
elements found to date are replication defective, many are related to gammaretrovi-
ruses currently circulating as infectious agents in a range of mammalian and avian
species (2). Moreover, the ability of gammaretroviruses to cross species boundaries is
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clear from the fossil record of endogenous viruses and from evidence of recent jumps
across wide species barriers, from rodents to primates (gibbon ape leukemia virus
[GaLV]) and marsupials (koala retrovirus [KoRV]) (3–5).
The long-standing observation of the ability of some variants of feline leukemia virus
(FeLV), a feline gammaretrovirus, to replicate to high titers in human cells in vitro led
to early concerns with regard to zoonotic spread (6, 7). FeLVs represent important
pathogens of the domestic cat that are capable of cross-species spread to endangered
feline species (8, 9). Despite widespread domestic contact with FeLV-infected cats,
which can shed virus in saliva and other body fluids, a series of careful studies has
shown no evidence of serological responses in exposed individuals (10). Human serum
factors that lyse or inactivate gammaretroviruses (11, 12) offer a significant obstacle to
cross-species spread but appear insufficient to account fully for resistance, since
sensitivity can be attenuated in viruses released by human cells after initial cell-cell
spread (13).
Our recent interest in the replication of FeLV in human cells was fueled by the desire
to use these agents as insertional mutagens and gene discovery tools in human cancer
cells in a manner similar to that of murine leukemia viruses (MLVs) in their natural host
(14, 15). In support of this goal, the ability of FeLV to integrate preferentially at strong
promoters and enhancers is also manifested in human cells infected in vitro (16).
However, it became apparent from our initial studies that the resistance of human cells
to FeLV is a multifaceted phenomenon that is likely to be relevant to cross-species
transfer, motivating us to conduct a deeper study.
FeLVs are a family of viruses that frequently occur as phenotypic mixtures in infected
cats (17, 18). Three major subgroups, which use different receptors to enter feline host
cells, have been described (17). Virtually all natural isolates contain a subgroup A FeLV
component (FeLV-A) that enters via the thiamine transporter THTR1 (19). This is the
major horizontally transmitted form of FeLV in cats but has been considered unlikely to
be zoonotic due to its low affinity for the human receptor homologue, hTHTR1 (19).
Many field isolates of FeLV consist of a mixture of FeLV-A and FeLV-B, the latter arising
by recombination and acquisition of envelope gene sequences from endogenous
FeLV-related sequences (20). FeLV-B isolates can replicate efficiently in at least some
cultured human cells with no cytopathic effect (6, 7, 17). Moreover, FeLV-B strains enter
via the widely expressed phosphate transporter Pit-1 and/or the related transporter
Pit-2 (21). Another human-cell-tropic variant is FeLV-C, which is generated by mutation
of the receptor-binding domain of Env (22), facilitating entry through the heme
transporter FLVCR1 or FLVCR2 (23, 24). However, FeLV-C isolates are rare in nature
(1% of isolates) (17) and presumably short-lived, due to their propensity to induce
rapidly fatal aplastic anemia (25). A further FeLV envelope variant that has been
described is the potently immunosuppressive FeLV-T, but this is also acutely patho-
genic and is stringently host-specific; its complex entry requirements include a trun-
cated envelope protein derived from endogenous FeLV-related proviruses that is
released by normal feline lymphoid cells (26, 27). Taken together, these biological
properties implicate FeLV-B strains as the most likely candidates for zoonotic spread.
While the study of HIV and other primate lentiviruses has identified many factors
that control host range by restricting replication (28), the gammaretroviruses have been
less well studied in this regard. MLVs have been shown to be highly sensitive to human
APOBEC3 cytidine deaminase activity but able to evade murine APOBEC3 (29, 30).
The effects of human APOBEC3 activity on FeLV have not been reported, although the
remarkable sequence stability of the commonly transmitted form of FeLV in the
domestic cat and its low mutation rate in the infection of other felids strongly suggests
that it has evolved to evade feline APOBEC activity (31, 32).
This study confirms FeLV-B as the variant most likely to have zoonotic potential,
since virtually all human cells are susceptible, with only limited postentry barriers to
infection. The resistance of primary blood cells at a postintegration step and potent
APOBEC3 induction of mutations in virions released from hematopoietic cells appear to
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be significant factors in limiting infectivity for human cells. The possibility that FeLV
could evolve to evade these barriers cannot be discounted.
RESULTS
Human cells display marked differences in susceptibility to FeLV-B infection.
The rationale for focusing on FeLV-B as the most likely zoonotic variant is presented in
Fig. 1A. FeLV-B is the most commonly occurring envelope variant with human cell
tropism and is formed by recombination with endogenous FeLV-related sequences (20)
(Fig. 1B). To generate FeLV-B virus stocks, the prototypic molecular clone of Gardner-
Arnstein FeLV-B was reconstituted by transfection, propagated in HEK293 cells, which
release high-titer FeLV-B into cell supernatants (105 to 106 infectious units/ml), and
titrated on feline QN10S cells (33). In initial experiments, it was noted that human cells
in culture were invariably susceptible to virus infection, but with markedly different
proviral copy numbers as assessed by Southern blotting or quantitative PCR. This
phenomenon was explored further in a dilution/spreading assay where cells were
exposed at decreasing multiplicities of infection (MOI) (from 1 to 104) and were
cultured for 2 weeks to allow virus spread before the harvest of cells and analysis of
FeLV proviral DNA by Southern blot hybridization. The detection of an internal 3.7-kb
genome fragment provides a quantitative estimate of FeLV DNA content, as shown in
Fig. 1C. Three distinct patterns were noted. HEK293 cells are permissive, and FeLV-B
spread rapidly to saturation after infection at a low MOI. At the other extreme, the
nonpermissive B-cell leukemia cell line Reh showed detectable proviral DNA only at an
MOI of 1. The myeloid leukemia cell line KYO-1 showed an intermediate, partially
permissive pattern, with the copy number diminishing in proportion to the infectious
challenge dose. Quantitative PCR analysis of DNA from cells infected at an MOI of 1
FIG 1 (A) Rationale for focusing on FeLV-B as the most likely zoonotic agent. The percentage of natural isolates containing each FeLV subgroup is given in
parentheses. (B) Outline of the molecular structure of FeLV-B proviruses that are derived by recombination between FeLV-A and endogenous (en) FeLV-related
proviruses in the feline genome. The hybridization probes (ExU3, EnvB) used to detect FeLV sequences in human cells are indicated. (C) The three basic patterns
of susceptibility of cultured human cells to infection with FeLV-B. Cells were exposed to FeLV-B at various multiplicities of infection and were passaged for 14
days before the extraction of high-molecular-weight DNA and analysis of FeLV proviral DNA content by Southern blot hybridization of KpnI-digested DNA with
the ExU3 probe. -ve, uninfected control. (D) Relative expression of mRNA encoding the FeLV-B receptor PIT-1 in a panel of cell lines sorted by the pattern of
FeLV-B spread (phenotype 1, 2, or 3, as exemplified in panel C).
FeLV Infection of Human Cells Journal of Virology
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indicated 30-fold-lower levels of FeLV DNA in Reh cells (0.3 copy/cell) than in
semipermissive KYO-1 cells, which displayed levels similar to those in permissive
controls (10 copies/cell).
As shown in Table 1, the infection/spread assay revealed full permissiveness (phe-
notype 1) for the replication of FeLV-B in 7 of 11 human cancer cell lines selected from
the NCI-60 cancer cell panel (https://dtp.cancer.gov/discovery_development/nci-60/
cell_list.htm). Smaller numbers of cancer cell lines were partially permissive (phenotype
2) or nonpermissive (phenotype 3), with no obvious relationship to the level of
expression of receptor PIT-1 mRNA as measured by quantitative reverse transcription-
PCR (qRT-PCR), which was in almost all cases higher than that for the permissive
HEK293 cell control) (Fig. 1D).
While spreading phenotype 1 was observed in multiple cancer cell lines, we noted
that Hs68 primary foreskin fibroblasts were more restrictive. To explore the possibility
that phenotype 1 is a feature of long-established cancer cell lines, we extended our
study to a panel of recently established pancreatic cancer cell lines (34) as well as other
nontransformed cells, including nonimmortalized CD34 cord blood cells, lung fibro-
blasts (IMR90), and immortalized but nontransformed skin keratinocytes (HaCAT).
Where cell numbers were limiting (e.g., for CD34 cells), FeLV DNA content was
analyzed by quantitative PCR. Pancreatic cancer cell lines displayed either the fully or
the partially permissive phenotype, while the partially permissive phenotype was also
observed in CD34 cord blood cells. The fully permissive phenotype was observed in
HaCAT and IMR90 cells, indicating that permissiveness is not simply a consequence of
oncogenic transformation. It is also noteworthy that we observed no evidence of
cytopathic effect or significant growth alteration in any of the FeLV-B-infected cell
TABLE 1 Differential susceptibilities of human cells to infection with FeLV-B
Phenotypea Cell lineb Origin
Fully permissive HEK293 Adenovirus-transformed immortalized human
embryonic kidney cells
MCF7* Mammary carcinoma
MDA-MB-231* Mammary carcinoma
HT29* Colon carcinoma
SW-620* Colon carcinoma
A549* Lung carcinoma
DU-145* Prostate carcinoma
PC-3* Prostate carcinoma
HT-1080 Fibrosarcoma
TKCC6 Pancreatic carcinoma
TKCC10 Pancreatic carcinoma
TKCC27LO Pancreatic carcinoma
MiPaCa2S Pancreatic carcinoma
Panc10.02 Pancreatic carcinoma
IMR90 Nonimmortalized lung fibroblasts
HaCAT Immortalized skin keratinocytes
Partially permissive KYO-1 Myeloid leukemia
CD34 Cord blood hematopoietic precursor
HeLa* Cervical carcinoma
TKCC7 Pancreatic carcinoma
TKCC9 Pancreatic carcinoma
TKCC14 Pancreatic carcinoma
TKCC15LO Pancreatic carcinoma
MALME3M* Melanoma
Hs68 Primary foreskin fibroblasts
Nonpermissive Reh B-cell leukemia
UACC-62* Melanoma
PEO1 Ovarian carcinoma
OVCAR-4* Ovarian carcinoma
RCC4 Renal carcinoma
aDefined according to a dilution/spread assay (Fig. 1C).
bAsterisks indicate NCI-60 panel cell lines.
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cultures, indicating that restricted viral spread was not due to loss of cell viability or
interference with cell division. In contrast, FeLV-C variants have marked cytopathic
effects in some cells (35).
Human hematopoietic cells display a partially permissive or nonpermissive
phenotype. The permissive spreading phenotype in multiple cancer cell lines is
associated with the release of high-titer FeLV at levels comparable to those in feline
fibroblast controls. To explore the basis of the restricted replication phenotypes in
greater depth, we examined the expression of intracellular viral antigen and virion
production in representative cell lines (KYO-1 and Reh) that were exposed to FeLV-B at
MOI of 1 and cultured for 2 weeks to allow viral spread. To explore the hypothesis
that hematopoietic cells are more widely resistant than other cell types, we extended
this analysis to a wider panel of hematopoietic cell lines as well as primary human
peripheral blood mononuclear cells (PBMCs). As shown in Fig. 2A, infected KYO-1 cells
express the FeLV precursor polyprotein Pr65Gag at levels similar to those in permissive
feline fibroblast cells (AH927), while Reh cells and PBMCs produce low or undetectable
levels. A similar divergence was noted when virion production was analyzed. At 14 days
postinfection, partially permissive KYO-1 cells showed sustained release of virions at
levels similar to those in permissive feline cells, while virion release by Reh cells and
PBMCs was low to undetectable (Fig. 2A). In a separate experiment, the virtual equiv-
alence of virion protein release was illustrated by serial dilution of pelleted virion
FIG 2 Human hematopoietic cells display two patterns of susceptibility to FeLV-B replication. (A) (Left)
Western blot (WB) analysis of the intracellular Gag precursor protein (Pr65Gag) in partially permissive
(phenotype 2) FeLV-B-infected KYO-1 cells shows expression levels similar to those in fully permissive feline
fibroblasts (AH927). In contrast, expression of Pr65Gag is barely detectable in nonpermissive Reh cells and
human PBMCs. (Right) This pattern is reflected in the levels of virus particle release, which are similar in
partially permissive KYO-1 cells and permissive AH927 cells, as illustrated by Western blot analysis of
pelleted virion preparations from equal volumes of culture medium. (B) Results of a separate experiment
where Western blot analysis of serial 2-fold dilutions of virions released from AH927 and KYO-1 cells again
showed levels of particle release from KYO-1 cells within a range similar to that for AH927 cells. (C) Western
blot analysis of pelleted virions harvested from cells 14 days after infection with FeLV-B. Equal volumes of
cell supernatant (2 ml) were sampled 24 h after medium change and were processed as described in
Materials and Methods.
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preparations prior to Western blot analysis (Fig. 2B). As shown in Fig. 2C and Table 2,
extending this analysis to a wider panel of hematopoietic cell lines showed that 9 of 13
leukemia cell lines displayed a KYO-1-like phenotype with sustained high-level release
of virions, while the other 4 resembled Reh cells, with very low to undetectable levels
of virus release. The level of permissiveness showed no clear pattern with regard to the
type of leukemia (B cell, T cell, myeloid, erythroleukemia) or the cytogenetic features of
the leukemia cell lines. PBMCs from four separate donors and a series of four Epstein-
Barr virus (EBV)-immortalized lymphoblastoid cell lines (LCLs) showed a low to non-
permissive phenotype in this assay. An assay for infectious FeLV released by these cells
revealed a similar pattern. Not surprisingly, cells with low virion release did not release
significant levels of infectious FeLV. However, virus released at high levels from partially
permissive lines showed very marked differences in specific infectivity, which was 4- to
104-fold lower than that of virus released from permissive feline cells. The CEM cell line
and its derivative CEMSS (36) were the most permissive lines tested, while Raji and
LAMA84 cells released the least infectious virions (Table 2).
The block to FeLV-B replication in nonpermissive cells occurs after reverse
transcription. To explore the basis of the nonpermissive phenotype in greater detail,
we examined the accumulation of proviral DNA after the exposure of cells to FeLV-B at
an MOI of 1. Notably, nonpermissive PBMCs accumulated levels of FeLV DNA similar to
those observed in partially permissive, high-virion-release KYO-1 cells (Fig. 3A). This was
not due to detection of preexisting DNA in virions, since only very low levels were
detected after the 30-min adsorption period, with significant increases by 6 h. To
confirm that this accumulation is a receptor-dependent process, we compared FeLV-A
infection of permissive feline lymphoma cells (3201 cells) to that of Reh cells, which do
not express detectable mRNA for the human receptor homologue THTR1. This control
was chosen because no PIT-1-negative cell lines were identified. The lack of accumu-
lation of proviral DNA in the receptor-negative cells supports the hypothesis that this
process is the result of receptor-mediated entry. The efficient detection of newly
synthesized DNA with either long terminal repeat (LTR) or envelope gene primers
suggests that complete proviral sequences are present, with no bias toward “strong-
stop” products (37).
More-extensive analysis of postadsorption amplification of proviral DNA by quanti-
tative PCR showed that all cells tested were initially permissive regardless of the later
TABLE 2 Human hematopoietic cell lines release FeLV-B virions with markedly different specific infectivities
Cell line Origina Level of virion releaseb FeLV titer (FFU/ml)c
HEK293 Human embryonic kidney cells High 105–106
AH927 Immortalized feline fibroblasts High 4  105
HT1080 Fibrosarcoma High 4  105
KYO-1 CML (blast crisis), t(9;22) High 3  103
CEM T-cell acute lymphoblastic leukemia High 4  104
CEMSS T-cell acute lymphoblastic leukemia High 6  104
Jurkat T-cell acute lymphoblastic leukemia High 4  102
K562 Erythroleukemia (CML blast crisis), t(9;22) High 103
Kasumi Acute myeloblastic leukemia High 3.5  102
LAMA84 Basophilic (CML blast crisis), t(9;22) High 1.3  101
Raji B-cell (Burkitt lymphoma), t(8;14) High 3  101
TOM-1 B-cell acute lymphocytic leukemia, t(9;22) High 1.6 101
KU812 Basophilic/erythroleukemia (CML blast crisis), t(9;22) High 2.3  103
Reh Pre-B-cell acute lymphocytic leukemia, t(12;21) Low 2  100
bv173 Undifferentiated blast, t(9;22) Low 2
ALL/MIK Pre-B-cell acute leukemia, t(9;22) Low/negative 5  101
EM2 Myeloblast (CML), t(9;22) Low/negative 2
KG-1 Acute myelogenous leukemia (M1) Low/negative 0
PBMC (n  4) Normal peripheral blood monocytic cells Negative 0
LCL (n  4) EBV-immortalized B-lymphoblastoid cell lines Low 0
aCML, chronic myeloid leukemia.
bMeasured at 14 days after infection with FeLV-B at an MOI of 1 (Fig. 2C).
cInfectious FeLV titer measured on QN10 (S L) cells. FFU, focus-forming units.
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outcome of infection (Fig. 3B). However, comparison of the quantitative change in DNA
from the 6-h time point to late infection (14 days) revealed a stark contrast between the
semipermissive, high-virion-release cells (e.g., CEM, Raji, and Jurkat cells), where copy
numbers increased over time, and the low-virion-output, nonpermissive cells (e.g.,
PBMCs and Reh cells), which showed unchanged or decreasing levels of proviral DNA.
Intriguingly, EBV-immortalized cell lines mainly fell into the partially permissive cate-
gory in this assay, suggesting that significant viral spread had occurred in these cells,
while day-14 analysis revealed only low levels of virion release with no detectable
infectivity. Again, we noted no cytopathic effect or changes in cell growth in these
experiments.
Integrated FeLV-B DNA persists in nonpermissive human PBMCs. Despite the
lack of proviral DNA amplification, we noted that FeLV-B DNA was readily detectable in
PBMCs at similar levels between 3 and 14 days after initial infection (Fig. 4A). This stable
association suggested that FeLV-B DNA may be integrated into PBMCs, and this
hypothesis was tested further by quantitative PCR after preamplification with a FeLV
Gag primer and a consensus human Alu repeat sequence (Fig. 4B). The greatly
enhanced detection of FeLV DNA after Alu-Gag preamplification indicates that much of
the DNA is in an integrated form. The possibility that FeLV DNA persists in an
unintegrated form was also tested by PCR for circular forms generated by ligation in the
nucleus. LTR circles were barely detectable in PBMCs and Reh cells by 3 days postin-
fection. Positive controls for this assay were early (24-h) samples from productively
infected 3201 and HEK293 cells, where single and double LTR circles were detected (Fig.
4C). Cloning and sequencing confirmed the identity of the single-LTR form (not shown).
Partially permissive cells display G-to-A hypermutation that correlates with
A3G mRNA expression. To explore the hypothesis that APOBEC cytidine deaminase
activity is involved in FeLV growth restriction, we analyzed proviral DNA after PCR
amplification of genome fragments from infected cells. These sequences were com-
FIG 3 Permissive and nonpermissive human cells support FeLV-B entry and early proviral DNA synthesis at similar levels.
(A) Initial studies using standard PCR with primers based on FeLV LTR or envelope sequences showed marked increases
in proviral DNA levels between 0.5 and 6 h after the exposure of cells to FeLV-B at an MOI of 1. Because no PIT-1-negative
cell lines were identified, a receptor-negative control was generated for this assay by comparing the FeLV-A infection of
permissive feline cells (3201 cells) and of Reh cells, which lack detectable expression of mRNA for the human homologue
of FeLV-A receptor THTR1. Loading controls used human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or
pan-Myc primers, which efficiently detect human and feline DNA. (B) A wider analysis of FeLV-B infection of human
hematopoietic cell lines. Proviral DNA levels were analyzed by quantitative PCR. The line graphs show changes in FeLV DNA
concentrations (detected by EnvB primers) relative to those of a housekeeping gene control (2-microglobulin) between
0.5 and 6 h (top) or between 6 h and 14 days (bottom) after infection. The y axis shows the threshold cycle (CT) value
relative to that of the 2-microglobulin control (taken as zero). Partially permissive cells were CEM, Jurkat, and Raji cells.
Nonpermissive cells were PBMCs (n 2), Reh cells, and ALL/MIK cells. Lymphoblastoid cell lines were LCL30, LCL98, LCL113,
and LCL114.
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pared to the index FeLV-B (pFGB) sequence for evidence of characteristic G¡A muta-
tions that are induced during reverse transcription (38). We found evidence of extensive
hypermutation of FeLV replicating in human cells at rates as high as 7 mutations/kb.
This mutation rate is much higher than the G¡A mutation rate reported for FeLV
replicating in cats in vivo (0.1/kb) (39), indicating that FeLV, like MLV (30), is able to
evade this restriction factor only in its natural host. FeLV strains typically encode a
glycosylated Gag precursor open reading frame (40), and this is intact in the Gardner-
Arnstein FeLV-B molecular clone. However, FeLV, like MLV, is sensitive to heterologous
human APOBEC3 activity (41). As shown in Fig. 5 with the examples of the Burkitt
lymphoma cell line Raji and the pancreatic cancer cell line TKCC15LO, mutational
footprints indicated that the predominant signature was GG¡GA, suggesting that
APOBEC3G (A3G) is responsible (42). Moreover, expression of A3G mRNA showed a
positive correlation with mutational activity when all cell lines were compared (R 
0.22; P 0.01). The results are collated in Fig. 5B and are broken down according to the
permissive (phenotype 1), partially permissive (phenotype 2) (high virion release), or
nonpermissive (phenotype 3) (low virion release) phenotype. Not surprisingly, permis-
sive cells showed low A3G expression and low mutational activity, while partially
permissive, high-virion-release cells showed high A3G expression and mutational ac-
tivity. In contrast, nonpermissive cells showed no evidence of hypermutation, indicat-
ing that a nonmutational mechanism of resistance is operative in these cells. Moreover,
a lack of mutation in PBMCs was observed despite very high levels of A3G, suggesting
that the proviral DNA detected was the result of initial reverse transcription rather than
FIG 4 Persistence of integrated FeLV-B DNA in human PBMCs. (A) Semiquantitative PCR reveals dose-dependent persis-
tence of FeLV DNA in human PBMCs at 14 days postinfection. Fully permissive HEK293 control cells show stable levels by
3 days postinfection. (B) Results of a quantitative PCR time course analysis for FeLV sequences in PBMC DNA, with and
without a preamplification step using primers to FeLV Gag and consensus human Alu sequences. The threshold cycle (CT)
value is inversely proportional to the DNA content. (C) Results of semiquantitative PCR for LTR circles in FeLV-B-infected
cells 3 days (PBMC, Reh, and KYO-1 cells) or 24 h (3201 and HEK293 cells) after infection. While single and double LTR circle
forms are readily detected in productively infected HEK293 and 3201 cells, they are barely detectable in Reh cells and
PBMCs relative to levels in permissive HEK293 control cells. The loading control was provided by PCR amplification with
conserved Myc primers (pan-Myc).
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secondary spread. The four LCLs showed significant levels of hypermutation (Fig. 5B,
center, dashed oval), supporting their grouping with the partially permissive cells on
the basis of proviral DNA accumulation (Fig. 3).
Analysis of all G¡A mutations in the cell lines with significant levels of hypermu-
tation (Fig. 5C) indicated that A3G is the major, though not the sole, effector of G¡A
mutations in the FeLV genome during replication in human cells. Notably, the two cell
lines with divergent signatures (Hs68 and KYO-1) displayed high levels of APOBEC3F
mRNA (not shown). The expression levels of A3G mRNA detected ranged over several
log units but were notably higher in cells of hematopoietic origin (Fig. 5D). The CEM cell
line and it derivative CEMSS showed the lowest levels among hematopoietic cell lines,
in agreement with their low mutation rates and high levels of release of relatively
noninfectious FeLV virions (Table 2). High levels of A3G mRNA relative to that in the
HEK293 control were also associated with restricted FeLV spread in nonhematopoietic
cells, but the majority of these lines showed low expression and a fully permissive
phenotype. However, as indicated in Fig. 5D, the nonpermissive phenotype (non-
spreading phenotype 3 [Table 1] and low proviral DNA accumulation [Fig. 3]) shows no
relationship with A3G expression or the mutation rate. This finding, taken together with
FIG 5 Hypermutation of the FeLV-B genome and APOBEC3G mRNA expression in human cells. FeLV genomic sequences (segments of Gag and Pol) were cloned
by PCR from infected human cells, and individual templates were sequenced and compared to the reference input virus (pFGB clone). APOBEC3G mRNA
expression was determined in the same cells (prior to infection) by quantitative real-time PCR (with SYBR green). (A) Representative plots of hypermutation
visualized by the online HYPERMUT program (www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html), where sequence changes relative to the
reference FeLV-B genome are color coded (red, GG¡AG; cyan, GA¡AA; green, GC¡AC; magenta, GT¡AT; black, non-G¡A). (B) X/Y plots of G¡A mutation
(per kilobase) against APOBEC3G mRNA levels (where the level in HEK293 cells is taken as 1) with cell lines sorted according to FeLV restriction phenotype.
Results for LCLs, which are discordant by virtue of their low levels of infectious virion release (Table 2) but postinfection accumulation of proviral DNA (Fig. 3),
are enclosed by a dashed oval. (C) Percentage of G¡A mutations that conform to the A3G signature (42) for all cell lines in which significant levels of mutations
were detected. Blue-gray bars, hematopoietic cells; yellow bars, nonhematopoietic cells. (D) Relative levels of APOBEC3G mRNA (on a log10 scale, with the level
in HEK293 cells taken as 1) for all the cell lines tested, sorted into hematopoietic (blue circles) and nonhematopoietic (green circles) cell lines. Nonpermissive
cells (nonspreading, with low virion release) are represented by black circles.
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evidence that this phenotype arises from a postintegration block to incoming virus,
suggests that this is an A3G-independent barrier.
DISCUSSION
FeLV-B strains are human-cell-tropic variants that are generated frequently during
FeLV infection in vivo (20, 43, 44) and are therefore of prime interest with respect to the
zoonotic potential of FeLV. This study demonstrated fully permissive or partially
permissive infection in a broad range of cancer-derived cell lines and in nontrans-
formed keratinocytes and lung fibroblasts. Cell lines of hematopoietic origin were
generally less permissive and were assigned to two discrete groups based on high or
low FeLV protein expression and virion release. Primary PBMCs and some EBV-
transformed LCLs were nonpermissive with respect to these measures (Fig. 1C and 2;
Table 2). While a spectrum of phenotypes was observed, this study revealed apparently
universal susceptibility of human cells to initial infection with FeLV-B, with no evidence
of a significant preintegration block to infection (Fig. 4); indeed, the early steps of
reverse transcription and integration appear to be unimpaired in nonpermissive cells
(Fig. 3 and 5A to C). However, at least two postintegration blocks to FeLV-B replication
appear to be operative in human cells. One block is clearly mediated by the APOBEC
system, as indicated by the high rates of G¡A mutations in FeLV in leukemia cell lines
that release abundant viral particles with low infectivity and in nonhematopoietic
cancer cell lines that display a partially permissive phenotype with respect to viral
spread (e.g., Raji and TKCC15LO cells, respectively) (Table 2; Fig. 3B and 5). The
predominant mutational signature was indicative of A3G in most cases, and we noted
a weak correlation between A3G mRNA expression and mutational activity across a
panel of cell lines (Fig. 5). This observation does not exclude the possibility that A3G
also inhibits by nonmutational mechanisms, such as inhibition of reverse transcription
(45).
The profound block to FeLV mRNA and protein expression in primary PBMCs (Fig. 2)
and to virus release from these cells occurred without detectable mutation, despite the
expression of high levels of A3G mRNA (Fig. 5), indicating a restriction that is A3G
independent. APOBEC3 proteins have also been reported to block incoming murine
retroviruses, and it appears that ectopic expression of A3A in mice can do so by a
nonmutational mechanism (41). However, as far as we are aware, there is no evidence
that APOBEC restriction can operate on incoming viruses after integration. Potential
mediators of postintegration suppression of incoming viruses include epigenetic reg-
ulators, such as those that are abundantly expressed in embryonal stem cells, and
restrict the expression of exogenous and endogenous retroelements (46). The possi-
bility that the resistance of PBMCs to FeLV reflects such a general resistance mechanism
against gammaretrovirus zoonosis merits further study. In this regard, we note reports
of profound restriction of xenotropic murine leukemia virus-related virus (XMRV)
growth in human PBMCs, which showed evidence of replication with G¡A mutations
only at extremely high levels of viral input (47).
With regard to relevance to zoonotic resistance, a key question is whether the
widespread susceptibility to FeLV replication observed in human cells reflects the
phenotype of the tissue of origin or a loss-of-function phenomenon due to oncogenic
transformation. The strongly restrictive phenotype of PBMC cultures, which contain a
rich variety of primary cell types, suggests that restriction is likely to represent an
important in vivo barrier. While the relative susceptibility of leukemia cell lines may be
due to loss of function, the similar phenotype observed in primary CD34 cells (Table
1) suggests that this may instead reflect an immature progenitor phenotype. Moreover,
many nonhematopoietic cell lines proved to be highly permissive for transcription,
virion assembly, and release of FeLV-B particles, with no evidence of APOBEC-mediated
mutations. Observation of this phenotype in IMR90 nontransformed lung fibroblasts,
for example, which retain the capacity for replicative senescence (48), as well as in
HaCAT skin keratinocytes, shows that susceptibility to infection can occur in the
absence of oncogenic transformation (Table 1). Moreover, the earliest description of
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productive FeLV replication in human cells was based on infection of HEL2000 primary
lung fibroblasts (6). In the case of transformed cells, it is difficult to discern whether the
relative susceptibility to FeLV represents a normal cellular state relevant to potential
zoonosis. While very-high-level A3G expression and mutational activity were observed
in the TKCC15LO pancreatic cancer cell line (Fig. 5), this may not reflect the normal
phenotype of pancreatic tissue. Upregulated A3G has been postulated to play a direct
oncogenic role in some pancreatic cancers (49).
The susceptibility of human cancer cells to spreading FeLV-B replication provides a
potentially instructive parallel with the mobilization and frequent reinsertion of L1
retrotransposons in50% of human cancers (50); high levels were noted in lung, colon,
prostate, and breast cancers, while the data sets for other tumor types showed few if
any new insertions in renal carcinomas and melanomas. These findings parallel the
present observations in that colon, lung, and breast cancer cell lines were fully
permissive to FeLV infection, but renal cancer cells and one melanoma line displayed
a strong early block to FeLV replication, with no evidence of APOBEC-mediated
mutations (Table 1; Fig. 5B). A further intriguing parallel is provided by a recent study
of XMRV pathogenesis in macaques, where intravenous inoculation of high-titer virus
led to the dissemination and persistence of viral protein expression, with the highest
levels in lung, colon, and prostate tissues (51). Taken together, these observations
suggest that susceptibility to infection may be the default state in some primary tissues.
Moreover, susceptibility to FeLV may provide a useful marker to aid in the identification
of further factors that confer tissue-specific susceptibility to genome instability in
cancer as well as resistance to incoming retroviruses.
Can the risk of zoonotic infection with FeLV be discounted? Despite control mea-
sures, including vaccination, that have reduced the prevalence of FeLV in some parts of
the world, this virus family remains one of the most important pathogens of cat species
worldwide (52). Moreover, the limited barriers protecting human cells against FeLV
infection contrast with the plethora of restriction factors that protect against the
cross-species transmission of primate lentiviruses, where recent jumps have occurred
(53). The successful transfer of other gammaretroviruses that use PIT-1 as an entry
receptor from rodents to primates (5) argues that future adaptation of FeLV for
zoonotic spread is not beyond the repertoire of this virus family. The possibility of
human exposure to high doses of FeLV analogous to those employed in recent primate
challenge experiments with XMRV (51, 54) is extremely remote; however, it may be
interesting to revisit the apparent lack of adaptive immune responses in exposed
individuals, e.g., veterinary workers (10), using more-sensitive techniques.
MATERIALS AND METHODS
Virus stocks. FeLV-B stocks were generated by transfection of an infectious molecular clone (pFGB)
(55) and propagation in the feline fibroblast cell line AH927 or HEK human embryonic kidney cells as
described previously (56). For FeLV-A stocks, HEK293 cells were transfected with pFGA-5 (20) to avoid
possible recombination and generation of FeLV-B (57). FeLV infectivity was determined by titration on S
L QN10 cells (33).
Cells. Cell lines were derived from curated frozen stocks maintained in our laboratory (Jurkat, K562,
CEM, Reh, Kasumi, U937, MCF-7) or by colleagues in the Glasgow Cancer Research UK Centre, including
A. Biankin (pancreatic cancer TKCC series) and T. Holyoake (chronic myeloid leukemia lines KYO-1, BV173,
KU812, LAMA84, and EM-2; B-cell acute lymphoblastic leukemia lines ALL/MIK and TOM-1). IMR90
fibroblasts were provided by P. Adams (48), while EBV-transformed lymphoblastoid cell lines (LCLs) were
obtained from R. Jarrett, and HaCAT keratinocytes were provided by S. Graham. CEMSS cells were kindly
provided by M. Malim (King’s College, London, United Kingdom). CD34 cells were purified by positive
selection using anti-CD34-conjugated magnetic microbeads (catalog no. 130-046-703; Miltenyi Biotec
Inc.) from cord blood samples generously provided by the Children’s Cancer and Leukemia Group (CCLG).
Primary blood mononuclear cells were obtained from Cambridge Bioscience (1 sample) and the Scottish
National Blood Transfusion Service (3 samples).
Dilution/spreading assay and Southern blot analysis. A total of 4  105 KYO-1 cells or Reh cells
or 5 104 HEK293 cells were plated per well in 6 wells of a 12-well plate the day before infection. FeLV-B
was harvested from subconfluent virus-producing HEK293 cells, filtered through 0.45-m filters, and
serially diluted 1:10 in RPMI 1640 medium with 10% fetal calf serum (FCS). A 0.5-ml volume of filtered
diluted virus was added per well, or medium alone was added to the control well, for 2 h. Cells were then
fed with fresh medium and were expanded as normal for 14 days. Genomic DNA was extracted from
phosphate-buffered saline (PBS)-washed, pelleted cells using a Qiagen DNeasy blood and tissue kit.
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Aliquots (15 g) of genomic DNA were digested overnight with KpnI, separated on a 0.8% agarose
Tris-acetate-EDTA (TAE) gel, transferred to a Hybond N membrane (Amersham) in 20  SSC (1 SSC is
0.15 M NaCl plus 0.015 M sodium citrate), and hybridized to FeLV ExU3 as described previously (21).
Quantitative real-time RT-PCR. RNA was extracted from cultured cells using a Qiagen RNeasy
minikit, and cDNA was synthesized from 1 g RNA using a Qiagen QuantiTect reverse transcription kit.
Aliquots (12.5 ng) of cDNA were amplified in triplicate using Power SYBR green PCR master mix (Thermo
Fisher Scientific) and Qiagen QuantiTect primer assays for human hypoxanthine phosphoribosyltrans-
ferase (HPRT) (QT00059066), APOBEC3G (QT00070770), SLC20A1 (PIT-1) (QT00028763), or SLC19A2
(THTR1) (QT00007847) on an ABI 7500 real-time PCR system. Quantification was carried out relative to
HEK293 cells, and values were normalized to HPRT expression.
Semiquantitative DNA PCR. One hundred-nanogram aliquots of genomic DNA were amplified in
Reddy Mix (Thermo Fisher Scientific) using primers FeLV envA F (5=-TAAAACACGGGGCACGTTAC-3=) and
FeLV envA R (5=-GGAGGTGGGCTTCCACCAAG-3=), FeLV envB F (5=-ATGTGATCAGCCTATGAGGA-3=) and
FeLV envB R (5=-CACTAGCTCCCGTTGTCGAG-3=), FeLV LTR F (5=-TAGCTGAAA CAGCAGAAGTTTCAAG-3=)
and FeLV LTR F R (5=-GGAAGGTCGAACTCTGGTCAAC-3=), and Myc F (5=-CCAACAGGAACTATGACCTCG-3=)
and Myc R (5=-GTAGAAGTTCTCCTCCTCGTC-3=). Samples were denatured at 94°C for 3 min and were then
subjected to 35 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Amplification products were
separated by electrophoresis on 2% agarose-TAE gels and were visualized by ethidium bromide staining.
DNA quantitative PCR. Genomic DNA was extracted by a Qiagen DNeasy minikit, and 20-ng aliquots
were amplified using primers for human 2 microglobulin (F, 5=-GGAATTGATTTGGGAGAGCAT-3=; R,
5=-CAGGTCCTGGCTCTACAATTTACTAA-3=), primers FeLV U3-LTR F (5=-TAGCTGAAA CAGCAGAAGTTTCAA
G-3=) and FeLV U3-LTR R (5=-GGAAGGTCGAACTCTGGTCAAC-3=), and primers envB F (5=CGGTATCCCGG
CAAGTAATG-3=) and envB R (5=-GGTTTTTGATCAGGCAGGACTAGA-3=) in Power SYBR green PCR master
mix. Amplification products were detected on an ABI 7500 real-time PCR system. Samples were
normalized to 2 microglobulin.
Western blotting. PBS-washed, pelleted cells were lysed in whole-cell lysis buffer and protein
concentrations measured by a Bio-Rad protein assay. Virion lysates were prepared from 2 ml precleared
virion supernatant by centrifugation in a Beckman TL100 benchtop ultracentrifuge for 2 h at 37,000 rpm
and 4°C. Virion pellets were resuspended in 75 l lysis buffer, and an equal volume (13 l) of virion
protein or 10-g aliquots of cellular protein were separated on 4-to-12% NuPAGE Novex Bis-Tris gels in
NuPAGE morpholinepropanesulfonic acid (MOPS) SDS buffer and were transferred to Hybond ECL
membranes (Amersham) in NuPAGE transfer buffer. Following overnight blocking in 5% milk in Tris-
buffered saline–Tween 20 (TBST), the filter was exposed to a 1:500 dilution of an anti-p27Gag monoclonal
antibody (VPG19.1; a gift of Brian Willett), and detection was carried out with the ECL detection reagent
(GE Healthcare).
Hypermutation analysis. FeLV gag or pol fragments were generated by amplification of 100-ng
aliquots of infected-cell genomic DNA in Reddy Mix PCR master mix (Thermo Fisher) using primers FeLV
p27gag F (5=-CCCAGTGGCCCTAACTAACC-3=) and R (5=-GCTGGCGTTTCCTCTTTCC-3=) or FeLV Pol F (5=-
GCAACCGGTAAGGTGACTC-3=) and Pol R (5=-TTCAAAGGGTTTGGTGATATCTG-3=). DNA was denatured at
94°C for 3 min and was then put through 35 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s.
Products were purified through Qiagen QIAquick PCR purification columns and were then cloned into
pCR2.1-TOPO (Invitrogen), transformed into TOP10 competent cells, and plated onto Amp X-Gal (5-
bromo-4-chloro-3-indolyl--D-galactopyranoside) agar plates. White colonies were cultured and plasmid
DNA extracted using Qiaprep spin preps, and DNA was sequenced from M13 F and M13 R primers by
Source BioScience and was examined for mutations relative to the pFGB molecular clone using Hyper-
mut, version 2.0.
Alu-Gag PCR. Primary PCR on 50 ng genomic DNA was performed in Platinum Taq DNA polymerase
(Invitrogen) using 10 M primers AluF (5=-GCCTCCCAAAGTGCTGGGATTACAG-3=) and FeLV gag R (5=-
ATAGGGAGGTGGCTCTTCTG-3=) at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 50°C for 15 s,
and 72°C for 3 min 30 s. Nested PCR was carried out on 4 l primary PCR product or 4 ng unamplified
DNA using primers FeLV RU5 F (5=-TCTTTGCTGAGACTTGACCG-3=) and FeLV RU5 R (5=-ACTAGGTCTTCC
TCGGCGAT-3=) and probe FeLV RU5 (5=-FAM-TGCATCTGACTCGTGGTCTC-TAMRA-3=) using Takyon Low-
Rox Probe Mastermix dTTP blue (UF-LPMT-BO101) (Eurogentec) and settings of 50°C for 2 min and 95°C
for 3 min, followed by 40 cycles of 95°C for 10 s and 60°C for 60 s on an ABI 7500 real-time PCR system.
LTR circle detection. Aliquots (100 ng) of genomic DNA from 3-day (PBMCs, Reh and KYO-1 cells) or
24-h (3201 and HEK293 cells) FeLV-infected cells were amplified in Reddy Mix PCR master mix with
primers Circles env F (5= TAAAACAGCGGCAACAACTG-3=) and Circles gag R (5=-GTCTCCGATCAACACCCT
GT-3=) or the positive-control primers pan-Myc 23F (5=-CCAACAGGAACTATGACCTCG-3=) and pan-Myc
96R (5=-GTAGAAGTTCTCCTCCTCGTC-3=). Following an initial denaturation step at 94°C for 3 min, 35
cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 1 min 30 s were performed. Portions (15 l) of each
25-l reaction mixture were separated on 1.4% agarose-TAE gels and were visualized by staining with
ethidium bromide.
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